These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23023563)

  • 21. Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.
    Pollock JA; Wardell SE; Parent AA; Stagg DB; Ellison SJ; Alley HM; Chao CA; Lawrence SA; Stice JP; Spasojevic I; Baker JG; Kim SH; McDonnell DP; Katzenellenbogen JA; Norris JD
    Nat Chem Biol; 2016 Oct; 12(10):795-801. PubMed ID: 27501397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.
    Zhang Y; Castaneda S; Dumble M; Wang M; Mileski M; Qu Z; Kim S; Shi V; Kraft P; Gao Y; Pak J; Sapra P; Bandaru R; Zhao H; Vessella RL; Horak ID; Greenberger LM
    Mol Cancer Ther; 2011 Dec; 10(12):2309-19. PubMed ID: 22027692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
    Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
    Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
    Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
    J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer.
    Zhan Y; Cao B; Qi Y; Liu S; Zhang Q; Zhou W; Xu D; Lu H; Sartor O; Kong W; Zhang H; Dong Y
    Int J Cancer; 2013 Nov; 133(9):2225-33. PubMed ID: 23575870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based virtual screening and identification of a novel androgen receptor antagonist.
    Song CH; Yang SH; Park E; Cho SH; Gong EY; Khadka DB; Cho WJ; Lee K
    J Biol Chem; 2012 Aug; 287(36):30769-80. PubMed ID: 22798067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.
    Andersen RJ; Mawji NR; Wang J; Wang G; Haile S; Myung JK; Watt K; Tam T; Yang YC; Bañuelos CA; Williams DE; McEwan IJ; Wang Y; Sadar MD
    Cancer Cell; 2010 Jun; 17(6):535-46. PubMed ID: 20541699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
    Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
    [No Abstract]   [Full Text] [Related]  

  • 30. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
    Sugawara T; Baumgart SJ; Nevedomskaya E; Reichert K; Steuber H; Lejeune P; Mumberg D; Haendler B
    Int J Cancer; 2019 Sep; 145(5):1382-1394. PubMed ID: 30828788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paradoxical androgen receptor regulation by small molecule enantiomers.
    Patsch K; Liu C; Zapotoczny G; Sun Y; Sura H; Ung N; Sun RX; Haliday B; Yu C; Aljehani M; Lee JSH; Kashemirov BA; Agus DB; McKenna CE; Ruderman D
    Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33741738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
    Jung ME; Ouk S; Yoo D; Sawyers CL; Chen C; Tran C; Wongvipat J
    J Med Chem; 2010 Apr; 53(7):2779-96. PubMed ID: 20218717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore.
    Koga H; Negishi M; Kinoshita M; Fujii S; Mori S; Ishigami-Yuasa M; Kawachi E; Kagechika H; Tanatani A
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.
    Ferroni C; Varchi G
    Curr Med Chem; 2019; 26(33):6053-6073. PubMed ID: 30209993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
    Gustafson JL; Neklesa TK; Cox CS; Roth AG; Buckley DL; Tae HS; Sundberg TB; Stagg DB; Hines J; McDonnell DP; Norris JD; Crews CM
    Angew Chem Int Ed Engl; 2015 Aug; 54(33):9659-62. PubMed ID: 26083457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
    Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
    Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen receptor antagonists: a patent review (2008-2011).
    Mohler ML; Coss CC; Duke CB; Patil SA; Miller DD; Dalton JT
    Expert Opin Ther Pat; 2012 May; 22(5):541-65. PubMed ID: 22583332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists.
    Roell D; Rösler TW; Hessenkemper W; Kraft F; Hauschild M; Bartsch S; Abraham TE; Houtsmuller AB; Matusch R; van Royen ME; Baniahmad A
    J Steroid Biochem Mol Biol; 2019 Apr; 188():59-70. PubMed ID: 30615932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.